Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK2823 in AML or MDS
NCT02181699Phase 1Terminated
- Sponsor
- Kyowa Kirin
- Start
- Jun 2014
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KHK2823 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Kyowa Kirin. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 12 weeks. Started Jun 2014; status: terminated.
02
Drugs
KHK2823
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02181699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181699.